Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02124668
Other study ID # 9785-CL-0122
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 23, 2014
Est. completion date May 25, 2017

Study information

Verified date October 2018
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 25, 2017
Est. primary completion date May 25, 2017
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Subject has histologically or cytologically confirmed adenocarcinoma of the prostate

- Subject has ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) and plans to maintain throughout the study period or has had a prior orchiectomy (i.e., surgical or medical castration)

- Subject has had at least one prior chemotherapy regimen for metastatic castration-resistant prostate cancer with at least one regimen containing docetaxel

- Subject has progressive disease and indication for change of antineoplastic regimen

- Subject has no known or suspected brain metastasis

- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Subject is able to swallow the study drug and comply with study requirements

- There is no comparable or satisfactory alternative therapy to treat the subject's disease

- Subject agrees not to participate in another interventional study while on treatment

Exclusion Criteria:

- Subject has severe concurrent disease, infection, or co-morbidity that would make the subject inappropriate for enrollment

- Subject's absolute neutrophil count is < 1000/µL, or platelet count < 100,000/µL, or hemoglobin < 6.2 mmol/L (or < 10 g/dL)

- Subject's total bilirubin is = 1.5 x upper limit of normal (ULN) (except for subjects with documented Gilbert's disease) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is = 2.5x ULN

- Subject's estimated creatinine clearance is less than 30 mL/min by the Cockcroft and Gault formula

- Subject has albumin = 30 g/L (or = 3.0 g/dL)

- Subject has received anti-androgen therapy (e.g. bicalutamide), chemotherapy, or biologic therapy for prostate cancer (other than bone targeted agents such as bisphosphonates or denosumab, gonadotropin-releasing hormone (GnRH) analogue therapy, or glucocorticoids which are allowed) within 4 weeks of Day 1

- Subject has had prior use of abiraterone

- Subject has prior use, or participation in a clinical trial, of an investigational agent that blocks androgen synthesis (e.g. TAK-700) or targets the androgen receptor (e.g. ARN-509, ODM-201)

- Subject has:

1. A history of seizure, including any febrile seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases,

2. A history of loss of consciousness or transient ischemic attack within 12 months of Screening

- Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome

- Subject has a significant cardiovascular disease

- Subject has received investigational therapy within 28 days or 5 half lives, whichever is longer, prior to Screening

- Subject has undergone major surgery within 4 weeks prior to Screening

- Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene

- Subject has used or plans to use, from 30 days prior to enrollment through the end of the study, medications known to lower the seizure threshold or prolong the QT interval

Study Design


Intervention

Drug:
Enzalutamide
oral

Locations

Country Name City State
Georgia Site GE99502 Tbilisi
Georgia Site GE99503 Tbilisi
Russian Federation Site RU70002 Moscow
Russian Federation Site RU70003 Moscow

Sponsors (2)

Lead Sponsor Collaborator
Astellas Pharma Europe B.V. Medivation, Inc.

Countries where clinical trial is conducted

Georgia,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety profile of enzalutamide assessed by adverse events (AEs), serious AEs (SAEs), vital signs, electrocardiograms (ECGs) and laboratory measurements Up to 30 days after the last dose of enzalutamide or prior to the initiation of another anticancer therapy, whichever comes first (up to 18 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A